Compare Canopy Growth Corp (CGC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs 10X Genomics Inc — how do they compare? Canopy Growth Corp trades at $1.02 (market cap $430.60M), while 10X Genomics Inc trades at $58.3 (market cap $7.52B). The key difference: 10X Genomics Inc is far larger — about 17.5× Canopy Growth Corp's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | TXG | |
|---|---|---|
Market Cap | $430.60M | $7.52B |
Sector | Health | Health |
52-Week High | $1.92 | $58.57 |
52-Week Low | $0.86 | $11.34 |
Enterprise Value | $388.01M | $7.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $1.01, up 1.0% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 fiscal 2027 revenue growth of 13% year-over-year, beating estimates, yet continues to post net losses. Recent news highlights expansion in European medical cannabis markets and cost-cutting efforts, while analyst consensus is mixed with 33% buy ratings.
Outlook remains speculative with high execution risk; improving cash flow trends and potential U.S. rescheduling offer upside, but persistent negative margins and debt concerns weigh on equity value. Investors should weigh growth prospects against profitability challenges in the volatile cannabis sector.
TXG trades at $58.15, down 0.5% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 earnings beating estimates, with revenue of $151 million and a loss per share of $0.14 versus an expected $0.24 loss. Gross margin improved to 70.03%, and cash flow from operations strengthened to $136 million in 2025. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook is mixed: analyst consensus is a Hold with a $48.38 price target below current levels, indicating caution despite recent earnings beats. Risks include persistent net losses, high valuation multiples like a P/S of 11.95, and competitive pressures in life sciences. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
